Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:2017:7021071.
doi: 10.1155/2017/7021071. Epub 2017 Jan 24.

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review

Giuseppe Di Iorio  1 , Gaia Baroni  2 , Marco Lorusso  2 , Chiara Montemitro  2 , Maria Chiara Spano  2 , Massimo di Giannantonio  1
Affiliations
Review

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review

Giuseppe Di Iorio et al. J Amino Acids. 2017.

Abstract

Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few years great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Glutamate is the main excitatory neurotransmitter in human CNS and it plays a prominent role in synaptic plasticity, learning, and memory and other cognitive functions. Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia. The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients. Our systematic review of the literature highlights that memantine therapy in schizophrenic patients seems to improve mainly negative symptoms while positive symptoms and cognitive symptoms did not improve significantly.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flowchart of the systematic review.
See this image and copyright information in PMC

References

    1. Matrisciano F., Tueting P., Dalal I., et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology. 2013;68:184–194. doi: 10.1016/j.neuropharm.2012.04.013. - DOI - PMC - PubMed
    1. Rapoport J. L., Giedd J. N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry. 2012;17(12):1228–1238. doi: 10.1038/mp.2012.23. - DOI - PMC - PubMed
    1. Olney J. W., Farber N. B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry. 1995;52(12):998–1007. - PubMed
    1. Balu D. T. Advances in Pharmacology. 1st. Elsevier; 2016. The NMDA receptor and schizophrenia: from pathophysiology to treatment; pp. 351–382. (Neuropsychopharmacology: A Tribute to Joseph T. Coyle). - DOI - PMC - PubMed
    1. Merritt K., McGuire P., Egerton A. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Frontiers in Psychiatry. 2013;4, article 151 doi: 10.3389/fpsyt.2013.00151. - DOI - PMC - PubMed

LinkOut - more resources